Stockscreener 앱 받기
41.57
0.51%
-0.1288
Enliven Therapeutics Inc 주식(ELVN)의 최신 뉴스
Enliven Therapeutics (ELVN) price target increased by 11.14% to 52.02 - MSN
Wall Street Zen Downgrades Enliven Therapeutics (NASDAQ:ELVN) to Sell - MarketBeat
Pictet Asset Management Holding SA Sells 94,852 Shares of Enliven Therapeutics, Inc. $ELVN - MarketBeat
Terns Buyout Deal Ignites Optimism For Enliven Therapeutics’s Blood Cancer Portfolio - MSN
Director sale notice — Enliven Therapeutics (NASDAQ: ELVN) files Form 144 - Stock Titan
[ARS] Enliven Therapeutics, Inc. SEC Filing - Stock Titan
Enliven Therapeutics (NASDAQ: ELVN) seeks larger share authorization - Stock Titan
We're Not Worried About Enliven Therapeutics' (NASDAQ:ELVN) Cash Burn - Sahm
Enliven Therapeutics (NASDAQ:ELVN) Stock Rating Upgraded by Wall Street Zen - MarketBeat
Enliven Therapeutics CMO Helen Collins sells over $238k in stock By Investing.com - Investing.com South Africa
Enliven Therapeutics CMO Helen Collins sells over $238k in stock - Investing.com Australia
Enliven Therapeutics (ELVN) CMO sells 5,000 shares after option exercise - Stock Titan
Trading the Move, Not the Narrative: (ELVN) Edition - Stock Traders Daily
Enliven Therapeutics (ELVN) Stock: Risk Analysis (Slight Loss) 2026-04-20Top Analyst Buy Signals - Cổng thông tin điện tử tỉnh Tây Ninh
Enliven Therapeutics (ELVN) Stock Investment Grade (Smart Money Active) 2026-04-18Crowd Trend Signals - UBND thành phố Hải Phòng
Enliven Therapeutics Stock Surges 194 Percent Amid CML Market Interest - HarianBasis.co
Enliven Therapeutics stock hits 52-week high at $46.83 By Investing.com - Investing.com India
Enliven Therapeutics (ELVN) soars to 5-year high as analysts 'upbeat' - MSN
Enliven Therapeutics (NASDAQ:ELVN) Hits New 1-Year HighTime to Buy? - MarketBeat
Enliven Therapeutics stock hits 52-week high at $46.83 - Investing.com
Enliven Therapeutics (ELVN) Up 194% This Year on Strong CML Market - Insider Monkey
Enliven (ELVN) gets higher price targets from HC Wainwright and Mizuho - MSN
Enliven Therapeutics, Inc. (NASDAQ:ELVN) Short Interest Down 26.3% in March - MarketBeat
Enliven Therapeutics (NASDAQ: ELVN) asks shareholders to approve charter share increase - Stock Titan
Enliven Therapeutics (NASDAQ:ELVN) Stock Price Down 4.2%What's Next? - MarketBeat
Enliven Therapeutics, Inc. (NASDAQ:ELVN) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
ELVN Earnings History & Surprises | EPS & Revenue Results | ENLIVEN THERAPEUTICS INC (NASDAQ:ELVN) - ChartMill
(ELVN) Volatility Zones as Tactical Triggers - Stock Traders Daily
ELVN Surges Amid Strategic Acquisition Talks and Analyst Upgrades - StocksToTrade
H.C. Wainwright reiterates Enliven Therapeutics stock rating on Terns deal details - Investing.com Canada
Merck’s Acquisition Ups Competition in Pharmaceuticals, Enliven Shines - timothysykes.com
Merck’s Acquisition Sparks Surge in Enliven Therapeutics - StocksToTrade
Enliven Therapeutics Regains Attention as Stock Prices Soar - timothysykes.com
Enliven Therapeutics stock hits 52-week high at $40.66 - Investing.com
Enliven Therapeutics stock hits 52-week high at $40.66 By Investing.com - Investing.com South Africa
Enliven (ELVN) Gets Higher Price Targets From H.C. Wainwright and Mizuho - Insider Monkey
Is Enliven Therapeutics (ELVN) Stock a Buy or Sell | Price at $38.94, Up 0.28%Trending Volume Leaders - Cổng thông tin điện tử Tỉnh Sơn La
5 Best Performing Stocks of Q1 2026 to Watch for Q2 - Insider Monkey
1.17%
3.22%
자본화:
|
볼륨(24시간):